Metabolic genes in cancer: their roles in tumor progression and
clinical implications by Furuta Eiji, Okuda Hiroshi, Kobayashi
Aya, Watabe Kounosuke in Biochimica et biophysica acta (2010).
PubMed   Re-programming of metabolic pathways is a hallmark of
physiological changes in cancer cells. The expression of certain
genes that directly control the rate of key metabolic pathways
including glycolysis, lipogenesis and nucleotide synthesis are
drastically altered at different stages of tumor progression.
These alterations are generally considered as an adaptation of
tumor cells; however, they also contribute to the progression of
tumor cells to become more aggressive phenotypes. This review
summarizes the recent information about the mechanistic link of
these genes to oncogenesis and their potential utility as
diagnostic markers as well as for therapeutic targets. We
particularly focus on three groups of genes; GLUT1, G6PD, TKTL1
and PGI/AMF in glycolytic pathway, ACLY, ACC1 and FAS in
lipogenesis and RRM2, p53R2